Kesmalea Therapeutics
Lior Soday is a Senior Scientist at Kesmalea Therapeutics with extensive experience in research, particularly focusing on the role of prenylation and farnesyl transferase inhibitors in cancer, as well as target identification studies. Lior's background includes a PhD in Natural Sciences from the University of Cambridge, where they also worked as a Researcher and Undergraduate Supervisor. Additionally, Lior has been involved in various research placements and projects in different institutions, showcasing a strong dedication to the field of medical science.
This person is not in any teams
Kesmalea Therapeutics
1 followers
Kesmalea is creating a new generation of protein homeostasis modulators, with a unique chemistry platform technology and therapeutic paradigm. Our novel approach allows us to overcome the challenges of existing protein degradation and stabilisation technologies, opening the door to previously unavailable oral therapeutics in areas of high unmet medical need. Protein homeostasis is the system of maintaining the equilibrium of proteins in the human body. This intricate system is in a constant state of change, with the body continuously synthesising and regulating proteins, whilst removing those which are no longer required (or have mutated) through controlled degradation. Small perturbations of the human body’s natural control mechanism that result in an excess or absence of certain proteins can drive the progression of disease. At Kesmalea, we’re aiming to counter this dysregulation with novel treatments which restore balance through effective protein degradation or stabilisation.